Rajaâ El Meskini

The paper identifies CLDN3 as a tumor-selective target in SCLC using proteogenomic analysis and validates its therapeutic potential with a monoclonal antibody.

This study shows that HDAC inhibition with entinostat enhances immunotherapy response in SCLC by reprogramming tumor immunology and neuroendocrine status.

This study identifies distinct metastatic phenotypes in cutaneous melanoma using clinico-genomic data and machine learning, linking specific mutations and clinical factors to organ-specific metastasis.

This study maps the SCLC tumor microenvironment and identifies cancer-associated fibroblasts as key drivers of neuroendocrine state plasticity and poor prognosis.